


Douglas W. Blayney

Professor of Medicine (Oncology)

Medicine - Oncology

 Resume available Online

CLINICAL OFFICES

- **Stanford Women's Cancer Center**

900 Blake Wilbur Dr

Palo Alto, CA 94304

Tel (650) 498-6004

Fax (650) 498-7237

Bio

BIO

Douglas W. Blayney, MD is a Professor of Medicine (Oncology) at Stanford, former Medical Director of Stanford Cancer Center, and specializes in the treatment of breast cancer. He has a special interest in the quality and value of cancer care. Dr. Blayney is a past president of the American Society of Clinical Oncology (ASCO), a founder of the ASCO Quality Symposium, a co-author of the ASCO value framework descriptions, and instigated the ASCO clinical "big data" effort, which is now CancerLinQ. He received the inaugural Ellen Stovall Award for Leadership in Patient Centered Care from the National Coalition for Cancer Survivorship in 2016. He was previously a Professor of Internal Medicine and Medical Director of the Comprehensive Cancer Center at the University of Michigan, and prior to that practiced and led Wilshire Oncology Medical Group, Inc. a physician owned multidisciplinary oncology practice in southern California. He has expertise on clinical trial development, use of oncology drugs in clinical practice, reimbursement and marketing strategies and information technology use.

Dr. Blayney's research interests include breast cancer, febrile neutropenia mitigation, and the use big data to improve cancer care quality and value. He has over 90 scientific publications. Dr. Blayney has served on the Food and Drug Administration's Oncologic Drugs Advisory Committee, and is Founding Editor-in-Chief and Editor-in-Chief Emeritus of ASCO's Journal of Oncology Practice. He has a degree in electrical engineering from Stanford, is a graduate of the University of California, San Diego School of Medicine, and received post graduate training at UCSD and at the National Cancer Institute in Bethesda, Maryland.

He is married, and has three grown daughters, one of whom is also a physician.

CLINICAL FOCUS

- Cancer > Breast Cancer
- Medical Oncology
- Cancer Care Value and Quality
- Cancer Survivorship

ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Oncology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- President, Wilshire Oncology Medical Group, Inc., (1996-2003)
- Medical Director, University of Michigan Comprehensive Cancer Center, (2003-2010)
- Medical Director, Stanford Cancer Center, (2010-2015)
- Medical Director for Quality, Stanford Cancer Institute, (2015-2022)

HONORS AND AWARDS

- Joseph V. Simone Award for Excellence in Quality and Safety in the Care of Patients with Cancer, American Society of Clinical Oncology (2018)
- The Ellen Stovall Award for Leadership in Patient-Centered Care, National Coalition for Cancer Survivorship (2016)
- President, American Society of Clinical Oncology (2009-10)
- Best Doctors in America, . (2007 - current)
- Fellow, American Society of Clinical Oncology (2007)
- Fellow, American College of Physicians (1991)

PROFESSIONAL EDUCATION

- Medical Education: University of California San Diego School of Medicine (1977) CA
- Residency: UCSD Internal Medicine Residency (1980) CA
- Fellowship: National Cancer Institute - Center Cancer Research (1983) MD
- Board Certification: Medical Oncology, American Board of Internal Medicine (1983)
- Board Certification: Internal Medicine, American Board of Internal Medicine (1980)
- Fellowship, Medicine Branch, National Cancer Institute, Bethesda, Maryland (1983)
- Fellowship, Environmental Epidemiology Branch, National Cancer Institute, Bethesda, Maryland (1983)
- Resident, University of California Hospitals, San Diego (1980)
- M.D., University of California, San Diego (1977)
- B.S.E.E., Stanford University (1972)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

During my tenure as Medical Director of the Stanford Cancer Institute (2010-15)

The Patient Experience, as measured by the Press-Ganey question “Likelihood to Recommend the Institution” for care, increased from the ninth percentile to consistently above the 90 percentile.

I co-led a task force that developed a strategic plan for the clinical operations of SCI, which was incorporated into a larger plan to transform cancer care at Stanford and nationwide. This plan resulted in a large gift, a substantial portion of which is allocated to Transform Cancer Care at Stanford and the nation (“the Transformation”).

Growth, as measured by new patient visits, increased by eleven percent year over year starting in fiscal year 2012, the year in which we set a goal to grow by fifty percent by 2017.

Stanford's Cancer Program has increased its ranking to number 10 in the nation for 2014 in the US News and World Report's (USNWR) latest ranking of cancer programs. Stanford ranked 14th in 2011. Cancer is the highest ranked Stanford Program in the USNWR system.

CLINICAL TRIALS

- A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study), Not Recruiting
- A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer, Not Recruiting
- A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC), Not Recruiting
- A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery, Not Recruiting
- A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer, Not Recruiting
- Brief Behavioral Intervention for Insomnia During Chemotherapy, Not Recruiting
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer, Not Recruiting
- Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer, Not Recruiting
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer, Not Recruiting

Publications

PUBLICATIONS

- **Cancer Biosimilars-A Regulatory Success So Far, but Value Still to Be Determined.** *JAMA oncology*
Blayney, D. W., Silver, S. M.
1800
- **Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.** *JAMA oncology*
Blayney, D. W., Zhang, Q., Feng, J., Zhao, Y., Bondarenko, I., Vynnychenko, I., Kovalenko, N., Nair, S., Ibrahim, E., Udovista, D. P., Mohanlal, R., Ogenstad, S., Ette, et al
2020
- **Better, Safer, Cheaper: Joseph V. Simone Award and Lecture.** *Journal of oncology practice*
Blayney, D. W.
2018; 14 (12): 763-66
- **Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN) Prevention, Mobilizes CD34+Cells through a Mechanism of Action (MoA) Different from G-CSF and from CXCR4 Inhibition**
Blayney, D. W., Ette, E., Ogenstad, S., Shi, Y., Du, L., Lloyd, K., Huang, L., Mohanlal, R.
AMER SOC HEMATOLOGY.2018
- **Efficacy of Medicaid for Patients With Cancer in California** *JAMA ONCOLOGY*
Blayney, D. W.
2018; 4 (3): 323-25
- **Critical Lessons From High-Value Oncology Practices** *JAMA ONCOLOGY*
Blayney, D. W., Simon, M. K., Podtschaske, B., Ramsey, S., Shyu, M., Lindquist, C., Milstein, A.
2018; 4 (2): 164-71
- **Developing a non-hormonal treatment for vaginal dryness for breast cancer survivors: A pilot study of a therapeutic ultrasound device**
David, S., Rockweiler, H., Krone, R., Middleton, S., Blayney, D.
AMER ASSOC CANCER RESEARCH.2018

- **Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.** *Journal of clinical oncology*
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Blayney, D. W., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., Lyman, G. H., Meropol, N. J., Mulvey, T., Newcomer, L., Peppercorn, et al
2016; 34 (24): 2925-2934
- **American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.** *Journal of clinical oncology*
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., Lyman, G. H., Meropol, N. J., Mulvey, et al
2015; 33 (23): 2563-2577
- **Do Wise Choices Translate Into Cost Savings and Improved Outcomes?** *Journal of oncology practice / American Society of Clinical Oncology*
Blayney, D. W.
2015; 11 (4): 344-345
- **Transforming data from information to quality improvement: a panel discussion with electronic health record vendors.** *Journal of oncology practice / American Society of Clinical Oncology*
Blayney, D. W.
2015; 11 (3): 174-175
- **Development and Future of the American Society of Clinical Oncology's Quality Oncology Practice Initiative** *JOURNAL OF CLINICAL ONCOLOGY*
Blayney, D. W., McNiff, K., Eisenberg, P. D., Gilmore, T., Jacobsen, P. B., Jacobson, J. O., Kadlubek, P. J., Neuss, M. N., Simone, J.
2014; 32 (35): 3907-U174
- **Breast cancer treatment across health care systems: linking electronic medical records and state registry data to enable outcomes research.** *Cancer*
Kurian, A. W., Mitani, A., Desai, M., Yu, P. P., Seto, T., Weber, S. C., Olson, C., Kenkare, P., Gomez, S. L., de Bruin, M. A., Horst, K., Belkora, J., May, et al
2014; 120 (1): 103-111
- **American society of clinical oncology 2013 top five list in oncology.** *Journal of clinical oncology*
Schnipper, L. E., Lyman, G. H., Blayney, D. W., Hoverman, J. R., Raghavan, D., Wollins, D. S., Schilsky, R. L.
2013; 31 (34): 4362-4370
- **ASCO's Quality Care Symposium (November 1-2, 2013) Abstracts** *JOURNAL OF CLINICAL ONCOLOGY*
Kuznetsov, J. L., Bailey, K., Bombach, P. K., Carmichael, S., Chen, X., Herberg, M. L., Owen, T., Wilson, J., Blayney, D. W.
2013; 31 (31)
- **Computerized prescriber order entry implementation in a physician assistant-managed hematology and oncology inpatient service: effects on workflow and task switching.** *Journal of oncology practice / American Society of Clinical Oncology*
Hanauer, D. A., Zheng, K., Commiskey, E. L., Duck, M. G., Choi, S. W., Blayney, D. W.
2013; 9 (4): e103-14
- **Measuring the Improving Quality of Outpatient Care in Medical Oncology Practices in the United States** *JOURNAL OF CLINICAL ONCOLOGY*
Neuss, M. N., Malin, J. L., Chan, S., Kadlubek, P. J., Adams, J. L., Jacobson, J. O., Blayney, D. W., Simone, J. V.
2013; 31 (11): 1471-1477
- **Tumor Boards (Team Huddles) Aren't Enough to Reach the Goal** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Blayney, D. W.
2013; 105 (2): 82-84
- **Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast Cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Hassett, M. J., Silver, S. M., Hughes, M. E., Blayney, D. W., Edge, S. B., Herman, J. G., Hudis, C. A., Marcom, P. K., Pettinga, J. E., Share, D., Theriault, R., Wong, Y., Vandergrift, et al
2012; 30 (18): 2218-2226
- **American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology** *JOURNAL OF CLINICAL ONCOLOGY*
Schnipper, L. E., Smith, T. J., Raghavan, D., Blayney, D. W., Ganz, P. A., Mulvey, T. M., Wollins, D. S.
2012; 30 (14): 1715-1724

- **Michigan Oncology Practices Showed Varying Adherence Rates To Practice Guidelines, But Quality Interventions Improved Care** *HEALTH AFFAIRS*
Blayney, D. W., Severson, J., Martin, C. J., Kadlubek, P., Ruane, T., Harrison, K.
2012; 31 (4): 718-728
- **Enhancing Quality Through Innovation: American Society of Clinical Oncology Presidential Address 2010** *JOURNAL OF CLINICAL ONCOLOGY*
Blayney, D. W.
2010; 28 (28): 4283-4288
- **Implementation of the Quality Oncology Practice Initiative at a University Comprehensive Cancer Center** *44th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Blayney, D. W., McNiff, K., Hanauer, D., Miela, G., Markstrom, D., Neuss, M.
AMER SOC CLINICAL ONCOLOGY.2009: 3802-7
- **Surgical solution for a paraneoplastic neurodegenerative disorder** *TRAUMA SURGERY & ACUTE CARE OPEN*
Muhammad, H., Strayve, D. G., Narayan, R. R., Blayney, D. W., Delitto, D.
2022; 7 (1)
- **Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.** *JAMA network open*
Blayney, D. W., Mohanlal, R., Adamchuk, H., Kirtbaya, D. V., Chen, M., Du, L., Ogenstad, S., Ginn, G., Huang, L., Zhang, Q.
1800; 5 (1): e2145446
- **Association of treatment type with patient-reported quality of life in cancer distress screening**
Roy, M., Rosenthal, S., Shah, M. P., Khaki, A., Bozkurt, S., Seto, T., Blayney, D. W., Hernandez-Boussard, T., Ramchandran, K.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Preventing 30-day readmissions for patients with cancer: A root-cause analysis**
Shah, M. P., Tan, I., Garrigues, S. K., Hansen, J., Blayney, D. W., Divi, V.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Spotlight on International Quality: COVID-19 and Its Impact on Quality Improvement in Cancer Care.** *JCO global oncology*
Blayney, D. W., Bariani, G., Das, D., Dawood, S., Gnant, M., De Guzman, R., Martin, S. E., O'Mahony, D., Roach, A., Ruff, P., Sampaio, C., Sanchez, J. A., Vanderpuye, et al
2021; 7: 1513-1521
- **Health management via telemedicine: Learning from the COVID-19 experience.** *Journal of the American Medical Informatics Association : JAMIA*
Sun, R., Blayney, D. W., Hernandez-Boussard, T.
2021
- **Headache outcomes of a sleep behavioral intervention in breast cancer survivors: Secondary analysis of a randomized clinical trial.** *Cancer*
Woldeamanuel, Y. W., Blayney, D. W., Jo, B., Fisher, S. E., Benedict, C., Oakley-Girvan, I., Kesler, S. R., Palesh, O.
2021
- **Diverse patient trajectories during cytotoxic chemotherapy: Capturing longitudinal patient-reported outcomes.** *Cancer medicine*
Azad, A. D., Yilmaz, M., Bozkurt, S., Brooks, J. D., Blayney, D. W., Hernandez-Boussard, T.
2021
- **Identification of patients at high risk for preventable emergency department visits and inpatient admissions after starting chemotherapy: Machine learning applied to comprehensive electronic health record data.**
Peterson, D. J., Ostberg, N. P., Blayney, D. W., Brooks, J. D., Hernandez-Boussard, T.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Impact of adding plinabulin to pegfilgrastim for the prevention of TAC chemotherapy (Chemo) induced neutropenia (CIN), on patient quality of life (QoL).**
Mohanlal, R., Lelorier, Y., Mitchell, D., Huang, L., Blayney, D. W.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention.**
Blayney, D. W., Shi, Y., Adamchuk, H., Feng, D., Zhang, Q., Du, L., Huang, L., Mohanlal, R.

LIPPINCOTT WILLIAMS & WILKINS.2021

- **Head-to-head comparison of single agent (SA) plinabulin (Plin) versus pegfilgrastim (Peg) for the prevention of chemotherapy-induced neutropenia (CIN) in the phase 3 trial PROTECTIVE-1.**
Blayney, D. W., Shi, Y., Bondarenko, I., Ogenstad, S., Zhang, Q., Du, L., Huang, L., Mohanlal, R.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Chemotherapy induced profound neutropenia (PN) in patients (pt) with breast cancer (BC) after chemotherapy and plinabulin (Plin) plus pegfilgrastim (Peg) combination versus (vs) peg alone: Final phase 3 results from protective-2 (BPI-2358-106).**
Shi, Y., Blayney, D. W., Adamchuk, H., Zhang, Q., Du, L., Huang, L., Mohanlal, R.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **EFFICACY OF BRIEF BEHAVIORAL THERAPY FOR HEADACHE MANAGEMENT IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY**
Woldeamanuel, Y., Blayney, D. W., Jo, B., Fisher, S., Benedict, C., Kesler, S., Oakley-Girvan, I., Palesh, O.
OXFORD UNIV PRESS INC.2021: S182
- **Protective-2 (bpi-2358-106): A confirmatory trial to demonstrate superiority of the plinabulin plus pegfilgrastim (plin/peg) combination versus standard of care pegfilgrastim for the prevention of chemotherapy-induced neutropenia (cin) in breast cancer (bc) patients (pts)**
Blayney, D. W., Huang, L., Mohanlal, R. W.
AMER ASSOC CANCER RESEARCH.2021
- **Differential efficacy of pegfilgrastim (Peg) in patients (pts) with breast cancer (BC) versus other cancer types for the prevention of docetaxel (Doc) chemotherapy-induced neutropenia (CIN)**
Blayney, D. W., Ginn, G., Huang, L., Mohanlal, R.
AMER ASSOC CANCER RESEARCH.2021
- **Plinabulin and pegfilgrastim (Plin plus Peg) versus peg monotherapy (Peg) after TAC: A comparison of efficacy, safety, relative dose intensity (RDI) and bone pain**
Blayney, D. W., Ginn, G., Huang, L., Mohanlal, R. W.
AMER ASSOC CANCER RESEARCH.2021
- **Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance.** *European urology open science*
Magnani, C. J., Bievre, N., Baker, L. C., Brooks, J. D., Blayney, D. W., Hernandez-Boussard, T.
2021; 23: 20–29
- **Machine Learning Applied to Electronic Health Records: Identification of Chemotherapy Patients at High Risk for Preventable Emergency Department Visits and Hospital Admissions.** *JCO clinical cancer informatics*
Peterson, D. J., Ostberg, N. P., Blayney, D. W., Brooks, J. D., Hernandez-Boussard, T.
2021; 5: 1106-1126
- **Treatment and Monitoring Variability in US Metastatic Breast Cancer Care.** *JCO clinical cancer informatics*
Caswell-Jin, J. L., Callahan, A., Purington, N., Han, S. S., Itakura, H., John, E. M., Blayney, D. W., Sledge, G. W., Shah, N. H., Kurian, A. W.
2021; 5: 600-614
- **Reply to Ritzwoller et al.** *JCO clinical cancer informatics*
Karimi, Y. H., Kurian, A. W., Blayney, D. W., Banerjee, I.
2021; 5: 1026-1027
- **Pioneering Cancer Quality: Lessons From Dr Joe Simone.** *JCO oncology practice*
Blayney, D. W.
2021: OP2100358
- **Severe neutropenia (grade 4, Gr4N) as a population-based predictor for adverse clinical outcome of chemotherapy induced neutropenia (CIN)**
Mohanlal, R., Ogenstad, S., Huang, L., Blayney, D.
ELSEVIER.2021: S1189-S1190
- **Prediction of febrile neutropenia (FN), hospitalization (Hosp) rates, and infection (Inf) rates in chemotherapy-induced neutropenia (CIN) patients (pts) treated with the plinabulin and pegfilgrastim combination (Plin plus Peg) using a meta-analysis (MA)-based tool**
Ogenstad, S., Blayney, D., Huang, L., Mohanlal, R.
ELSEVIER.2021: S1190

- **Impact of adding plinabulin to pegfilgrastim for the prevention of chemotherapy induced neutropenia (CIN) on patient quality of life (QoL)**
Blayney, D., Le Lorier, Y., Mitchell, D., Huang, L., Mohanlal, R.
ELSEVIER.2021: S1190
- **Limited English Proficiency and Disparities in Health Care Engagement Among Patients With Breast Cancer.** *JCO oncology practice*
Roy, M. n., Purington, N. n., Liu, M. n., Blayney, D. W., Kurian, A. W., Schapira, L. n.
2021: OP2001093
- **Development and Use of Natural Language Processing for Identification of Distant Cancer Recurrence and Sites of Distant Recurrence Using Unstructured Electronic Health Record Data.** *JCO clinical cancer informatics*
Karimi, Y. H., Blayney, D. W., Kurian, A. W., Shen, J. n., Yamashita, R. n., Rubin, D. n., Banerjee, I. n.
2021; 5: 469–78
- **Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model.** *JCO oncology practice*
Neal, J. W., Roy, M. n., Bugos, K. n., Sharp, C. n., Galatin, P. S., Falconer, P. n., Rosenthal, E. L., Blayney, D. W., Modaressi, S. n., Robinson, A. n., Ramchandran, K. n.
2021: OP2000473
- **Benchmark Method for Cost Computations across Healthcare Systems: Cost of Care per Patient per Day in Breast Cancer Care** *JCO Oncology Practice*
Blayney, D. W., Seto, T., Hoang, N., Lindquist, C., Kurian, A. W.
2021
- **Plinabulin (Plin) is a more favorable option for the prevention of chemotherapy induced neutropenia (CIN) than pegfilgrastim (Peg) during the COVID-19 pandemic**
Blayney, D., Mohanlal, R., Huang, L.
ELSEVIER.2020: S1008
- **Real-world outcomes of patients with metastatic breast cancer (BC) treated with osteoclast inhibitors (OIs).**
Karimi, Y., Purington, N., Liu, M., Kurian, A. W., Sledge, G. W., Blayney, D. W.
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Development and validation of natural language processing (NLP) algorithm for detection of distant versus local breast cancer recurrence and metastatic site.**
Karimi, Y., Blayney, D. W., Kurian, A. W., Rubin, D., Banerjee, I.
AMER SOC CLINICAL ONCOLOGY.2020
- **Four distinct patient-reported outcome (PRO) trajectories in longitudinal responses collected before, during, and after chemotherapy.**
Blayney, D. W., Azad, A., Yilmaz, M., Bozkurt, S., Brooks, J. D., Hernandez-Boussard, T.
AMER SOC CLINICAL ONCOLOGY.2020
- **Distress screening through PROMIS at an academic cancer center and network site: Implementation of a hybrid model.**
Roy, M., Neal, J. W., Bugos, K., Sharp, C., Falconer, P., Rosenthal, E., Blayney, D. W., Modaressi, S., Robinson, A., Ramchandran, K.
AMER SOC CLINICAL ONCOLOGY.2020
- **A comparison of CD34+mobilization effects of standard dose pegfilgrastim (Peg) versus low-dose peg combined with plinabulin (Plin).**
Blayney, D. W., Huang, L., Mohanlal, R. W.
LIPPINCOTT WILLIAMS & WILKINS.2020
- **International Perspective on the Pursuit of Quality in Cancer Care: Global Application of QOPI and QOPI Certification.** *JCO global oncology*
Blayney, D. W., Abdelhafeez, N., Jazieh, A. R., Pinto, C. F., Udrea, A., Roach, A., Das, D., Grubbs, S., Hamm, J., Jahanzeb, M., Kamal, A. H., Kelly, R. J., Martin, et al
2020; 6: 697–703
- **Computing the Cost of Care Per Day for Patients With Metastatic NETs**
Gupta, D., Kapphahn, K., Qin, F., Hornbacker, K., Henry, S., Wood, D., Blayney, D., Kunz, P.
LIPPINCOTT WILLIAMS & WILKINS.2020: 470
- **Leveraging Digital Data to Inform and Improve Quality Cancer Care.** *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*
Hernandez-Boussard, T., Blayney, D. W., Brooks, J. D.

2020

- **Clinical Documentation to Predict Factors Associated with Urinary Incontinence Following Prostatectomy for Prostate Cancer.** *Research and reports in urology*
Li, K., Banerjee, I., Magnani, C. J., Blayney, D. W., Brooks, J. D., Hernandez-Boussard, T.
2020; 12: 7-14
- **Cortical Brain Age from Pre-treatment to Post-chemotherapy in Patients with Breast Cancer.** *Neurotoxicity research*
Henneghan, A. n., Rao, V. n., Harrison, R. A., Karuturi, M. n., Blayney, D. W., Palesh, O. n., Kesler, S. R.
2020
- **Clinical Documentation to Predict Factors Associated with Urinary Incontinence Following Prostatectomy for Prostate Cancer** *RESEARCH AND REPORTS IN UROLOGY*
Li, K., Banerjee, I., Magnani, C. J., Blayney, D. W., Brooks, J. D., Hernandez-Boussard, T.
2020; 12: 7-14
- **Association between patient-initiated emails and overall 2-year survival in cancer patients undergoing chemotherapy: Evidence from the real-world setting.** *Cancer medicine*
Coquet, J. n., Blayney, D. W., Brooks, J. D., Hernandez-Boussard, T. n.
2020
- **Clinical Evidence Against the Continuum of Low-Primed Uncommitted Hematopoietic and Progenitor Cells (CLOUD-HSPC) Concept for Hematopoiesis**
Mohanlal, R., Blayney, D. W., Huang, L.
AMER SOC HEMATOLOGY.2019
- **Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN)**
Blayney, D. W., Huang, L., Mohanlal, R.
AMER SOC HEMATOLOGY.2019
- **A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (plin) plus Pegfilgrastim (peg) Versus (vs) Peg Alone for Tac (docetaxel, doxorubicin, cyclophosphamide) Induced Neutropenia (cin)**
Blayney, D. W., Huang, L., Mohanlal, R.
AMER SOC HEMATOLOGY.2019
- **Impact of mortality reviews on supportive care utilization, end-of-life care, and inpatient mortality.**
Karimi, Y., Divi, V., Srinivas, S., Smith, A., Hansen, J., Tokareva, I., Tulu, Z., Hedlin, H., Fronk, J., Rosenthal, E., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2019
- **Quality of Life in NSCLC Patients Treated with Docetaxel and Either Plinabulin or Pegfilgrastim for Prevention of Neutropenia**
Blayney, D., Mitchell, D., Lelorier, Y., Huang, L., Mohanlal, R.
ELSEVIER SCIENCE INC.2019: S359
- **The effect of increasing doses of pegfilgrastim (Peg) on thrombocytopenia (T) in breast cancer (BC) patients (pts) receiving taxotere (Doc), doxorubicin, cyclophosphamide (TAC) and plinabulin (Plin)**
Blayney, D. W., Bondarenko, I., Shi, Y., Ogenstad, S., Du, L., Huang, L., Mohanlal, R.
OXFORD UNIV PRESS.2019: 737
- **Extracting Patient-Centered Outcomes from Clinical Notes in Electronic Health Records: Assessment of Urinary Incontinence After Radical Prostatectomy.** *EGEMS (Washington, DC)*
Gori, D., Banerjee, I., Chung, B. I., Ferrari, M., Rucci, P., Blayney, D. W., Brooks, J. D., Hernandez-Boussard, T.
2019; 7 (1): 43
- **Comparison of orthogonal NLP methods for clinical phenotyping and assessment of bone scan utilization among prostate cancer patients** *JOURNAL OF BIOMEDICAL INFORMATICS*
Coquet, J., Bozkurt, S., Kan, K. M., Ferrari, M. K., Blayney, D. W., Brooks, J. D., Hernandez-Boussard, T.
2019; 94
- **Comparison of pegfilgrastim (Peg), plinabulin (Plin), and the combination for chemotherapy (Chemo) induced neutropenia (CIN) prevention: Rationale for the combination.**
Blayney, D. W., Ogenstad, S., Shi, Y., Zhang, Q., Feng, J., Sun, T., Du, L., Huang, L., Mohanlal, R.

AMER SOC CLINICAL ONCOLOGY.2019

- **Real-world efficacy of bone modifying agents (BMAs) in patients with breast cancer (BC) treated in an academic health system: Use of the "green button.**
Karimi, Y., Gombar, S., Dean, L., Hansen, J., Callahan, A., Jung, K., Divi, V., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2019
- **REDUCTION IN PATIENT REPORTED BONE PAIN WITH PLINABULIN VS PEGFILGRASTIM IN NON SMALL CELL LUNG CANCER PATIENTS TREATED FOR THE PREVENTION OF DOCETAXEL-INDUCED NEUTROPENIA**
Blayney, D., Mitchell, D., Lelorier, Y., Huang, L., Mohanlal, R.
ELSEVIER SCIENCE INC.2019: S109
- **Distribution of Global Health Measures From Routinely Collected PROMIS Surveys in Patients With Breast Cancer or Prostate Cancer** *CANCER*
Seneviratne, M. G., Bozkurt, S., Patel, M., Seto, T., Brooks, J. D., Blayney, D. W., Kurian, A. W., Hernandez-Boussard, T.
2019; 125 (6): 943–51
- **A phase II trial with the combination of plinabulin (plin) pegfilgrastim (peg): Evaluation of the reversal of peg's immune-suppressive potential by the addition of plin to peg.**
Blayney, D. W., Ogenstad, S., Shi, Y., Feng, J., Zhang, Q., Sun, T., Du, L., Huang, L., Mohanlal, R.
AMER SOC CLINICAL ONCOLOGY.2019
- **"DID YOU FEEL THE EARTH SHAKE?" AN ONLINE CANCER COMMUNITY INTERPRETS RESULTS OF A PRACTICE-CHANGING TRIAL**
Hall, E., Schapira, L., Zeiger, R., Blayney, D. W., Trivedi, R.
OXFORD UNIV PRESS INC.2019: S39
- **Utilization of Prostate Cancer Quality Metrics for Research and Quality Improvement: A Structured Review** *JOINT COMMISSION JOURNAL ON QUALITY AND PATIENT SAFETY*
Gori, D., Dulal, R., Blayney, D. W., Brooks, J. D., Fantini, M. P., McDonald, K. M., Hernandez-Boussard, T.
2019; 45 (3): 217–26
- **A randomized clinical trial of the combination of Plinabulin (Plin) plus Pegfilgrastim (Peg) versus (vs) Peg alone for TAC (docetaxel, doxorubicin, cyclophosphamide) induced Neutropenia (CIN)**
Blayney, D., Ogenstad, S., Shi, Y., Zhang, Q., Sun, T., Du, L., Huang, L., Mohanlal, R.
CHURCHILL LIVINGSTONE.2019: S21
- **PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Magnani, C. J., Li, K. n., Seto, T. n., McDonald, K. M., Blayney, D. W., Brooks, J. D., Hernandez-Boussard, T. n.
2019; 17 (7): 795–803
- **Machine Learning Approaches for Extracting Stage from Pathology Reports in Prostate Cancer.** *Studies in health technology and informatics*
Lenain, R. n., Seneviratne, M. G., Bozkurt, S. n., Blayney, D. W., Brooks, J. D., Hernandez-Boussard, T. n.
2019; 264: 1522–23
- **Predicting Patient Reported Outcomes of Cognitive Function Using Connectome-Based Predictive Modeling in Breast Cancer.** *Brain topography*
Henneghan, A. M., Gibbons, C. n., Harrison, R. A., Edwards, M. L., Rao, V. n., Blayney, D. W., Palesh, O. n., Kesler, S. R.
2019
- **Comparison of Orthogonal NLP Methods for Clinical Phenotyping and Assessment of Bone Scan Utilization among Prostate Cancer Patients.** *Journal of biomedical informatics*
Coquet, J. n., Bozkurt, S. n., Kan, K. M., Ferrari, M. K., Blayney, D. W., Brooks, J. D., Hernandez-Boussard, T. n.
2019: 103184
- **Is it possible to automatically assess pretreatment digital rectal examination documentation using natural language processing? A single-centre retrospective study.** *BMJ open*
Bozkurt, S. n., Kan, K. M., Ferrari, M. K., Rubin, D. L., Blayney, D. W., Hernandez-Boussard, T. n., Brooks, J. D.
2019; 9 (7): e027182
- **Better, Safer, Cheaper: Joseph V. Simone Award and Lecture** *JOURNAL OF ONCOLOGY PRACTICE*
Blayney, D. W.
2018; 14 (12): 763+

- **Plinabulin, a Novel Immuno-Oncology Agent Mitigates Docetaxel Chemotherapy -Induced-Neutropenia and -Thrombocytopenia in NSCLC Patients**
Blayney, D., Ogenstad, S., Shi, Y., Zhang, Q., Du, L., Huang, L., Mohanlal, R.
ELSEVIER SCIENCE INC.2018: S461
- **Can measuring quality lead to improvement? Evidence from international participants of ASCO's quality oncology practice initiative (QOPI) during 2015-2017.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Jahanzeb, M., Gilmore, T., Roach, A., Grubbs, S. S., Blayney, D., Hamm, J., Kamal, A., Kelly, R. J., Martin, E., Sanchez, J. A., Siegel, R., Crist, S. T., Rosenthal, et al
2018; 29 Suppl 8: viii571
- **Plinabulin (Plin), a novel non-G-CSF molecule for the revention of chemotherapy-induced neutropenia (CIN), has the potential to positively impact tumor micro environment.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Blayney, D., Ogenstad, S., Shi, Y., Zhang, Q., Du, L., Huang, L., Mohanlal, R.
2018; 29 Suppl 8: viii604
- **Can measuring quality lead to improvement? Evidence from international participants of ASCO's quality oncology practice initiative (QOPIV (R)) during 2015-2017**
Jahanzeb, M., Gilmore, T., Roach, A., Grubbs, S. S., Blayney, D., Hamm, J., Kamal, A., Kelly, R. J., Martin, E., Sanchez, J. A., Siegel, R., Crist, S. S., Rosenthal, et al
OXFORD UNIV PRESS.2018: 571
- **Plinabulin (Plin), a novel non-G-CSF molecule for the revention of chemotherapy-induced neutropenia (CIN), has the potential to positively impact tumor micro environment**
Blayney, D., Ogenstad, S., Shi, Y., Zhang, Q., Du, L., Huang, L., Mohanlal, R.
OXFORD UNIV PRESS.2018
- **Oncologists' Views on Using Value to Guide Cancer Treatment Decisions** *VALUE IN HEALTH*
Gidwani-Marszowski, R., Nevedal, A. L., Blayney, D. W., Patel, M., Kelly, P., Timko, C., Ramchandran, K., Murrell, S. S., Asch, S. M.
2018; 21 (8): 931-37
- **Architecture and Implementation of a Clinical Research Data Warehouse for Prostate Cancer.** *EGEMS (Washington, DC)*
Seneviratne, M. G., Seto, T., Blayney, D. W., Brooks, J. D., Hernandez-Boussard, T.
2018; 6 (1): 13
- **Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase (phi) 2 results from a head-to-head comparison with Pegfilgrastim (Peg).**
Blayney, D. W., Shi, Y., Bondarenko, I., Zhang, Q., Kovalenko, N., Feng, J., Vynnychenko, I., Kopp, M., Ogenstad, S., Du, L., Huang, L., Mohanlal, R. W.
AMER SOC CLINICAL ONCOLOGY.2018
- **CHANGES IN PROSTATE SPECIFIC ANTIGEN SCREENING AND PROSTATE CANCER DIAGNOSIS AFTER GUIDELINE CHANGES**
Magnani, C. J., Li, K., Seto, T., McDonald, K. M., Blayney, D. W., Brooks, J. D., Hernandez-Boussard, T.
ELSEVIER SCIENCE INC.2018: E520
- **Computing the cost of care per day of breast cancer survivor care.**
Blayney, D. W., Lindquist, C., Seto, T., Nhat Minh Hoang, Kurian, A. W.
AMER SOC CLINICAL ONCOLOGY.2018
- **Practice-based evidence for factors associated with urinary incontinence following prostate cancer care.**
Li, K., Magnani, C. J., Bozkurt, S., Seto, T., Blayney, D. W., Brooks, J. D., Hernandez-Boussard, T.
AMER SOC CLINICAL ONCOLOGY.2018
- **Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer.** *Cancer*
Seneviratne, M. G., Bozkurt, S. n., Patel, M. I., Seto, T. n., Brooks, J. D., Blayney, D. W., Kurian, A. W., Hernandez-Boussard, T. n.
2018
- **Myeloid Growth Factors, Version 2.2017 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Crawford, J., Becker, P., Armitage, J. O., Blayney, D. W., Chavez, J., Curtin, P., Dinner, S., Fynan, T., Gojo, I., Griffiths, E. A., Hough, S., Kloth, D. D., Kuter, et al
2017; 15 (12): 1520+

- **Predicting Long-Term Cognitive Outcome Following Breast Cancer with Pre-Treatment Resting State fMRI and Random Forest Machine Learning** *FRONTIERS IN HUMAN NEUROSCIENCE*
Kesler, S. R., Rao, A., Blayney, D. W., Oakley-Girvan, I. A., Karuturi, M., Palesh, O.
2017; 11: 555
- **Therapeutic Ultrasound as a Novel, Non-hormonal Treatment of Vulvo-vaginal Atrophy: A Pilot Phase II Study**
MacLaughlan, S., Rockweiler, H., Krone, R., Middleton, S., Blayney, D.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2017: 235
- **Redesigning Cancer Care Delivery: Views From Patients and Caregivers.** *Journal of oncology practice*
Patel, M. I., Periyakoil, V. S., Blayney, D. W., Moore, D., Nevedal, A., Asch, S., Milstein, A., Coker, T. R.
2017; 13 (4): e291-e302
- **The Appropriate Provision of Primary versus Specialist Palliative Care to Cancer Patients: Oncologists' Perspectives** *JOURNAL OF PALLIATIVE MEDICINE*
Gidwani, R., Nevedal, A., Patel, M., Blayney, D. W., Timko, C., Ramchandran, K., Kelly, P. A., Asch, S. M.
2017; 20 (4): 395-403
- **A natural language processing algorithm to measure quality prostate cancer care.**
Hernandez-Boussard, T., Kourdis, P., Dulal, R., Ferrari, M., Henry, S., Seto, T., McDonald, K., Blayney, D. W., Brooks, J. D.
AMER SOC CLINICAL ONCOLOGY.2017
- **Quality, clinician and information technology (IT) partnership for metric reporting.**
Smith, A., Porter, J., Badwe, A., Kiamanesh, E. F., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2017
- **Increasing Epic staging module adherence in an academic cancer center**
Porter, J., Smith, A., Cook, M., Boncato, K., Bruels, M., Duda-Stavlund, E., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2017
- **Improving care with portfolio of physician-led cancer quality measures at an academic center**
Porter, J., Smith, A., Winget, M., Rosenthal, E., Seshadri, S., Vetteth, Y., Kiamanesh, E. F., Badwe, A., Advani, R. H., Buyyounouski, M. K., Coutre, S., Dorigo, O., Ganjoo, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Disrupted brain network functional dynamics and hyper-correlation of structural and functional connectome topology in patients with breast cancer prior to treatment** *BRAIN AND BEHAVIOR*
Kesler, S. R., Adams, M., Packer, M., Rao, V., Henneghan, A. M., Blayney, D. W., Palesh, O.
2017; 7 (3)
- **Implementing a Method for Evaluating Patient-Reported Outcomes Associated With Oral Oncolytic Therapy.** *Journal of oncology practice*
Mackler, E., Petersen, L., Severson, J., Blayney, D. W., Benitez, L. L., Early, C. R., Hough, S., Griggs, J. J.
2017: JOP2016018390-?
- **Survivorship care plan: Use of the 'Oncology History' (OncHx) feature of the Epic electronic health record (EHR).**
Bugos, K., Foran, J., Petree, J. M., Sabati, K., Bruels, M., Cook, M., Mishra, P., Barahimi, H., Cook, A., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2017
- **Patient reported symptom severity in cancer survivors.**
Bugos, K., Foran, J., Sabati, K., Valdez, A., Petree, J. M., Wellman, C., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2017
- **Establishing a Core Set of Performance Measures to Improve Value in Cancer Care: ASCO Consensus Conference Recommendation Report** *JOURNAL OF ONCOLOGY PRACTICE*
Neuss, M., Rocque, G., Zuckerman, D., Chiang, A., Katta, S., Wollins, D., Kamin, D., Edge, S.
2017; 13 (2): 135-+
- **Mining Electronic Health Records to Extract Patient-Centered Outcomes Following Prostate Cancer Treatment.** *AMIA ... Annual Symposium proceedings. AMIA Symposium*
Hernandez-Boussard, T., Kourdis, P. D., Seto, T., Ferrari, M., Blayney, D. W., Rubin, D., Brooks, J. D.

2017; 2017: 876–82

- **Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center** *Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center*
Porter, J. B.
2017; 13 (8): e673-e682
- **Choosing Wisely in Oncology: Are We Ready For Value-Based Care?** *Journal of oncology practice*
Rocque, G. n., Blayney, D. W., Jahanzeb, M. n., Knape, A. n., Markham, M. J., Pham, T. n., Shelton, J. n., Sudheendra, P. n., Evans, T. n.
2017; 13 (11): e935–e943
- **Plinabulin, a Novel Small Molecule That Ameliorates Chemotherapy-Induced Neutropenia, Is Administered on the Same Day of Chemotherapy and Has Anticancer Efficacy**
Blayney, D. W., Bazhenova, L., Lloyd, G., Huang, L., Mohanlal, R.
AMER SOC HEMATOLOGY.2016
- **Where Does Dynamic Value Assessment Fit Into Our Role as Agents Advising Our Patients With Cancer?** *JOURNAL OF ONCOLOGY PRACTICE*
Blayney, D. W.
2016; 12 (12): 1211–13
- **Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival.** *Journal of clinical oncology*
Partridge, A. H., Hughes, M. E., Warner, E. T., Ottesen, R. A., Wong, Y., Edge, S. B., Theriault, R. L., Blayney, D. W., Niland, J. C., Winer, E. P., Weeks, J. C., Tamimi, R. M.
2016; 34 (27): 3308-3314
- **What role should value play in cancer care?**
Gidwani, R., Blayney, D. W., Patel, M. I., Asch, S. M., Kelly, A., Nevedal, A.
AMER SOC CLINICAL ONCOLOGY.2016
- **The ideal interface between oncology and palliative care: Views from the field.**
Gidwani, R., Blayney, D. W., Patel, M. I., Asch, S. M., Kelly, P., Nevedal, A.
AMER SOC CLINICAL ONCOLOGY.2016
- **Using technology to improve quality metric adherence**
Jacobsen, P. B., Gaguski, M., Thomas, K. A., Hathaway, A., Halilova, K. I., Stricker, C., Hammelef, K., Panzer, S., Blayney, D. W., Rocque, G.
AMER SOC CLINICAL ONCOLOGY.2016
- **Achieving the triple aim in cancer care through a tri-part research collaboration.**
Patel, M. I., Ramirez, D., Nguyen, A., Hagan, C., Asch, S. M., Agajanian, H. H., Agajanian, R., Milstein, A., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2016
- **Using technology to improve patient-provider communication and delivery of quality care.**
Rocque, G., Hathaway, A., Halilova, K. I., Gaguski, M., Thomas, K. A., Stricker, C., Hammelef, K., Panzer, S., Jacobsen, P. B., Buzaglo, J. S., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2016
- **Using a web analytic tool to evaluate Pathways program engagement in 36 Michigan oncology practices.**
Seung, A., Justus, R., Klamerus, J., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2016
- **Choosing Wisely in oncology: Are we ready for value-based care?**
Rocque, G., Blayney, D., Jahanzeb, M., Kadlubek, P., Knape, A., Markham, M., Trang Pham, Evans, T. L.
AMER SOC CLINICAL ONCOLOGY.2016
- **Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors.** *JAMA oncology*
Kesler, S. R., Blayney, D. W.
2016; 2 (2): 185-192
- **New Paradigms for Patient-Centered Outcomes Research in Electronic Medical Records: An Example of Detecting Urinary Incontinence Following Prostatectomy.** *EGEMS (Washington, DC)*
Hernandez-Boussard, T., Tamang, S., Blayney, D., Brooks, J., Shah, N.
2016; 4 (3): 1231-?

- **Is screening enough? Implications of a pilot utilizing standard screening criteria for early palliative referral**
Ramchandran, K., Winget, M., Tribett, E. L., Anderson, B., Morris, A., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2015
- **From PRO screening to improved wellness: A nurse-led intervention**
Morris, A., Tribett, E. L., Tun, S., Winget, M., Blayney, D. W., Ramchandran, K.
AMER SOC CLINICAL ONCOLOGY.2015
- **American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.** *Journal of clinical oncology*
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., Lyman, G. H., Meropol, N. J., Mulvey, et al
2015; 33 (23): 2563-2577
- **Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer** *NEUROBIOLOGY OF AGING*
Kesler, S. R., Watson, C. L., Blayney, D. W.
2015; 36 (8): 2429-2442
- **Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.** *Journal of clinical oncology*
Warner, E. T., Tamimi, R. M., Hughes, M. E., Ottesen, R. A., Wong, Y., Edge, S. B., Theriault, R. L., Blayney, D. W., Niland, J. C., Winer, E. P., Weeks, J. C., Partridge, A. H.
2015; 33 (20): 2254-2261
- **Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.** *Journal of clinical oncology*
Warner, E. T., Tamimi, R. M., Hughes, M. E., Ottesen, R. A., Wong, Y., Edge, S. B., Theriault, R. L., Blayney, D. W., Niland, J. C., Winer, E. P., Weeks, J. C., Partridge, A. H.
2015; 33 (20): 2254-2261
- **Association of high symptom burden with oral oncolytic agents**
Severson, J., Mackler, E. R., Marini, B., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2015
- **Choosing wisely: Treatment recommendations from 36 Michigan Oncology Clinical Treatment Pathways practices**
Seung, A., Hamel, L. M., Stella, P. J., Klamerus, J., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2015
- **Leveraging state cancer registries to measure and improve the quality of cancer care: a potential strategy for California and beyond.** *Journal of the National Cancer Institute*
Hiatt, R. A., Tai, C. G., Blayney, D. W., Deapen, D., Hogarth, M., Kizer, K. W., Lipscomb, J., Malin, J., Phillips, S. K., Santa, J., Schrag, D.
2015; 107 (5)
- **American society of clinical oncology third quality care symposium.** *Journal of oncology practice / American Society of Clinical Oncology*
Earle, C. C., Jacobson, J. O., Blayney, D. W.
2015; 11 (3): 167-?
- **Detecting unplanned care from clinician notes in electronic health records.** *Journal of oncology practice / American Society of Clinical Oncology*
Tamang, S., Patel, M. I., Blayney, D. W., Kuznetsov, J., Finlayson, S. G., Vetteh, Y., Shah, N.
2015; 11 (3): e313-9
- **Administration of oral chemotherapy: results from three rounds of the quality oncology practice initiative.** *Journal of oncology practice / American Society of Clinical Oncology*
Zerillo, J. A., Pham, T. H., Kadlubek, P., Severson, J. A., Mackler, E., Jacobson, J. O., Blayney, D. W.
2015; 11 (2): e255-62
- **Are Patients With Thoracic Malignancies at Risk for Uncontrolled Symptoms?** *Journal of oncology practice / American Society of Clinical Oncology*
Patel, M. I., Williams, D. C., Wohlforth, C., Fisher, G., Wakelee, H. A., Blayney, D. W.
2015; 11 (1): e98-e102
- **Using a statewide collaborative approach to improve tobacco cessation referral rates for cancer patients**

Severson, J., Baca, H., Blayney, D., Brown, K., Galiyas, G., Minasian, M., Schmidt, J., Schulze, A., Warren, G.
AMER ASSOC CANCER RESEARCH.2014

- **Reply to L.k. Griffeth et Al and j.e. Battley et Al.** *Journal of clinical oncology*
Schnipper, L. E., Schilsky, R. L., Hoverman, J. R., Raghavan, D., Lyman, G. H., Wollins, D. S., Blayney, D. W.
2014; 32 (25): 2812-2813
- **Mobile cognitive assessment battery (MCAB) for assessment of cancer-related cognitive changes.**
Kesler, S., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2014
- **Improved access to tobacco cessation services for cancer patients using a statewide collaborative approach.**
Severson, J., Baca, H., Blayney, D. W., Brown, K., Galiyas, G., Minasian, M., Schmidt, J., Schulze, A., Warren, G.
AMER SOC CLINICAL ONCOLOGY.2014
- **Survivorship care plan: Use of the "Oncology History" (OnCHx) feature of the Epic electronic health record (EHR).**
Bugos, K., Mishra, P., Bruels, M., Laport, G., Herring, B., Pose, K., Williamson, C. E., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2014
- **Oral chemotherapy performance indicators: Early results from three rounds of Quality Oncology Practice Initiative (QOPI) data**
Zerillo, J. A., Trang Pham, Kadlubek, P., Severson, J., Mackler, E., Jacobson, J. O., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2014
- **Transforming cancer care: are transdisciplinary approaches using design-thinking, engineering, and business methodologies needed to improve value in cancer care delivery?** *Journal of oncology practice / American Society of Clinical Oncology*
Patel, M. I., Moore, D., Blayney, D. W., Milstein, A.
2014; 10 (2): e51-4
- **Breast Cancer Treatment Across Health Care Systems** *CANCER*
Kurian, A. W., Mitani, A., Desai, M., Yu, P. P., Seto, T., Weber, S. C., Olson, C., Kenkare, P., Gomez, S. L., de Bruin, M. A., Horst, K., Belkora, J., May, et al
2014; 120 (1): 103-111
- **Patients with systemic lupus erythematosus and haematological malignancy at a tertiary care centre: timing, histopathology and therapy.** *Lupus science & medicine*
Knight, J. S., Blayney, D. W., Somers, E. C.
2014; 1 (1)
- **Real-time extraction of breast cancer treatment process and outcome measures from an EPIC electronic health record (EHR)**
Kuznetsov, J., Bailey, K., Bombach, P. K., Carmichael, S., Chen, X., Herberg, M., Owen, T., Wilson, J., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2013
- **Using a statewide collaborative approach to improve tobacco cessation referral rates for cancer patients**
Severson, J., Baca, H., Blayney, D. W., Brown, K., Galiyas, G., Minasian, M., Notier, A., Schmidt, J., Warren, G.
AMER SOC CLINICAL ONCOLOGY.2013
- **PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER**
Ramchandran, K. J., Fronk, J., Trieu, S., Wakelee, H. A., Das, M., Neal, J. W., Harman, S., Dwyer, P., Bosch, J., Shaw, H., Safari, S., Oden, R., Morrison, et al
LIPPINCOTT WILLIAMS & WILKINS.2013: S1324
- **Are patients' needs being met after hours? An evaluation of phone calls made after hours for patients with thoracic malignancies.**
Patel, M. I., Moore, D., Milstein, A., Wakelee, H. A., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2013
- **ARE PATIENTS' NEEDS BEING MET AFTER-HOURS? AN EVALUATION OF PHONE CALLS MADE AFTER HOURS FOR PATIENTS WITH THORACIC MALIGNANCIES.**
Patel, M. I., Williams, D., Wohlforth, C., Fisher, G. A., Blayney, D., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2013: S709
- **Myeloid Growth Factors** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*

- Crawford, J., Armitage, J., Balducci, L., Becker, P. S., Blayney, D. W., Cataland, S. R., Heaney, M. L., Hudock, S., Kloth, D. D., Kuter, D. J., Lyman, G. H., McMahon, B., Rugo, et al
2013; 11 (10): 1266-1290
- **Are needs of stakeholders in cancer care being met? A novel approach to assessing needs to improve value in cancer care**
Patel, M. I., Moore, D., Randolph, S., Wakelee, H. A., Blayney, D. W., Milstein, A.
AMER SOC CLINICAL ONCOLOGY.2013
 - **Measuring and improving quality of care in an academic medical center.** *Journal of oncology practice / American Society of Clinical Oncology*
Blayney, D. W.
2013; 9 (3): 138-141
 - **Introduction to the ASCO Quality Care Symposium** *JOURNAL OF ONCOLOGY PRACTICE*
Blayney, D. W., Stovall, E. L., Earle, C. C.
2013; 9 (3): 113
 - **Models That Work: Incorporating Quality Principles in Different Clinical Settings** *JOURNAL OF ONCOLOGY PRACTICE*
Krzyzanowska, M. K., Blayney, D. W., Bosserman, L. D., Sullivan, T.
2013; 9 (3): 135-37
 - **Time to diagnosis and breast cancer stage by race/ethnicity** *BREAST CANCER RESEARCH AND TREATMENT*
Warner, E. T., Tamimi, R. M., Hughes, M. E., Ottesen, R. A., Wong, Y., Edge, S. B., Theriault, R. L., Blayney, D. W., Niland, J. C., Winer, E. P., Weeks, J. C., Partridge, A. H.
2012; 136 (3): 813-821
 - **Measuring the improving quality of outpatient care in medical oncology practices in the United States**
Neuss, M. N., Malin, J., Chan, S., Kadlubek, P., Adams, J. L., Joseph, J., Blayney, D., Simone, J. V.
AMER SOC CLINICAL ONCOLOGY.2012
 - **The use of a palliative care tool in a community private practice**
Mahmood, T., Shock, H., Severson, J., Blayney, D. W., Michigan Oncology Quality Consorti
AMER SOC CLINICAL ONCOLOGY.2012
 - **Clinicopathologic Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network** *CANCER*
Lin, N. U., Vanderplas, A., Hughes, M. E., Theriault, R. L., Edge, S. B., Wong, Y., Blayney, D. W., Niland, J. C., Winer, E. P., Weeks, J. C.
2012; 118 (22): 5463-5472
 - **The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy** *QUALITY OF LIFE RESEARCH*
Kleinman, L., Benjamin, K., Viswanathan, H., Mattera, M. S., Bosserman, L., Blayney, D. W., Revicki, D. A.
2012; 21 (7): 1255-1266
 - **The Effect of Age on Delay in Diagnosis and Stage of Breast Cancer** *ONCOLOGIST*
Partridge, A. H., Hughes, M. E., Ottesen, R. A., Wong, Y., Edge, S. B., Theriault, R. L., Blayney, D. W., Niland, J. C., Winer, E. P., Weeks, J. C., Tamimi, R. M.
2012; 17 (6): 775-782
 - **Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database** *BLOOD*
LaCasce, A. S., Vandergrift, J. L., Rodriguez, M. A., Abel, G. A., Crosby, A. L., Czuczman, M. S., Nademanee, A. P., Blayney, D. W., Gordon, L. I., Millenson, M., Vanderplas, A., Lepisto, E. M., Zelenetz, et al
2012; 119 (9): 2093-2099
 - **Age and Survival in Women with Early Stage Breast Cancer: An Analysis Controlling for Tumor Subtype.**
Partridge, A. H., Hughes, M. E., Ottesen, R., Wong, Y., Edge, S. B., Theriault, R. L., Blayney, D. W., Niland, J. C., Winer, E. P., Weeks, J. C., Tamimi, R. M.
AMER ASSOC CANCER RESEARCH.2011
 - **The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers** *BREAST CANCER RESEARCH AND TREATMENT*
Brewster, A. M., Etzel, C., Zhou, R., Wong, Y., Edge, S., Blayney, D. W., Wilson, J., Hudis, C., Ottesen, R., Hughes, M. E., Weeks, J. C., Theriault, R. L.
2011; 130 (3): 897-904

- **Commentary: six years of trends in oncology practice data.** *Journal of oncology practice / American Society of Clinical Oncology*
Blayney, D. W.
2011; 7 (5): 291-293
- **Myeloid Growth Factors** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Crawford, J., Allen, J., Armitage, J., Blayney, D. W., Cataland, S. R., Heaney, M. L., Htoy, S., Hudock, S., Kloth, D. D., Kuter, D. J., Lyman, G. H., McMahon, B., Steensma, et al
2011; 9 (8): 914-?
- **Institutional Variation in the Surgical Treatment of Breast Cancer A Study of the NCCN** *ANNALS OF SURGERY*
Greenberg, C. C., Lipsitz, S. R., Hughes, M. E., Edge, S. B., Theriault, R., Wilson, J. L., Carter, W. B., Blayney, D. W., Niland, J., Weeks, J. C.
2011; 254 (2): 339-345
- **Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence?** *ONCOLOGIST*
Wong, Y., Ottesen, R. A., Hughes, M. E., Niland, J. C., Theriault, R., Edge, S. B., Blayney, D., Weeks, J. C.
2011; 16 (5): 559-565
- **Expansion of cancer care and control in countries of low and middle income: a call to action** *LANCET*
Farmer, P., Frenk, J., Knaul, F. M., Shulman, L. N., Alleyne, G., Armstrong, L., Atun, R., Blayney, D., Chen, L., Feachem, R., Gospodarowicz, M., Gralow, J., Gupta, et al
2010; 376 (9747): 1186-1193
- **Impact of CPOE on workflow and direct patient care time in an inpatient hematology/oncology service.**
Hanauer, D. A., Zheng, K., Choi, S. W., Beasley, R., Schumacher, J., Duck, M., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2010
- **Gene expression profile testing for breast cancer: Patterns and predictors of use and impact on chemotherapy.**
Hassett, M. J., Niland, J. C., Hughes, M. E., Theriault, R. L., Blayney, D. W., Wong, Y., Hudis, C., Marcom, P. K., Laronga, C., Weeks, J. C.
AMER SOC CLINICAL ONCOLOGY.2010
- **The effect of age on delay in diagnosis and stage of breast cancer**
Partridge, A. H., Hughes, M. E., Wong, Y., Edge, S. B., Theriault, R. L., Blayney, D. W., Niland, J. C., Winer, E. P., Weeks, J. C., Tamimi, R. M.
AMER SOC CLINICAL ONCOLOGY.2010
- **Use of a 21-gene reverse transcriptase-polymerase chain reaction (RT-PCR) assay to guide therapy in 14 Michigan Breast Oncology Quality Initiative (MiBOQI) sites**
Silver, S. M., Ali, H. Y., Blayney, D. W., Caughran, J., Herman, J. G., Pettinga, J. E., Share, D., Mehringer, A., Hayes, A., Vandergrift, J. L.
AMER SOC CLINICAL ONCOLOGY.2010
- **Challenges to National Cancer Institute-Supported Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites.** *Journal of oncology practice / American Society of Clinical Oncology*
Baer, A. R., Kelly, C. A., Bruinooge, S. S., Runowicz, C. D., Blayney, D. W.
2010; 6 (3): 114-117
- **Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database**
Abel, G. A., Vanderplas, A., Friedberg, J. W., Niland, J., Rodriguez, M. A., Czuczman, M. S., Millenson, M., Crosby, A. L., Gordon, L. I., Blayney, D. W., Zelenetz, A. D., LaCasce, A. S.
AMER SOC HEMATOLOGY.2009: 565
- **R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project**
LaCasce, A., Vandergrift, J. L., Rodriguez, M. A., Crosby, A. L., Lepisto, E. M., Czuczman, M. S., Nademanee, A. P., Blayney, D. W., Gordon, L. I., Millenson, M., Vanderplas, A., Abel, G. A., Zelenetz, et al
AMER SOC HEMATOLOGY.2009: 167-168
- **Partnering with payers for success: quality oncology practice initiative, blue cross blue shield of michigan, and the michigan oncology quality consortium.** *Journal of oncology practice / American Society of Clinical Oncology*
Blayney, D. W., Stella, P. J., Ruane, T., Martin, J., Lavoisier, B., Leyden, T., Malloy, M.

2009; 5 (6): 281-284

- **Lymphoma After Solid Organ Transplantation: Risk, Response to Therapy, and Survival at a Transplantation Center** *49th Annual Meeting of the American-Society-of-Hematology*
Knight, J. S., Tsodikov, A., Cibrik, D. M., Ross, C. W., Kaminski, M. S., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2009: 3354–62
- **Introduction of computerized provider order entry (CPOE) and time impact in an inpatient hematology/oncology service: Serial time and motion studies**
Hanauer, D. A., Beasley, R. W., Schumacher, J., Duck, M. G., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2009
- **Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN)**
Lin, N. U., Vanderplas, A., Hughes, M. E., Theriault, R. L., Edge, S. B., Wong, Y., Blayney, D. W., Niland, J. C., Winer, E. P., Weeks, J. C.
AMER SOC CLINICAL ONCOLOGY.2009
- **Quality of breast cancer care in NCCN centers as assessed by the ASCO/NCCN quality measures: Overall performance and reasons for nonconcordance**
Hughes, M. E., Ottesen, R., Niland, J. C., Edge, S. B., Theriault, R. L., Wilson, J., Blayney, D. W., Wong, Y., Weeks, J. C.
AMER SOC CLINICAL ONCOLOGY.2009
- **The impact of obesity on adherence to the National Comprehensive Cancer Network (NCCN) guidelines recommending chemotherapy for patients with operable breast cancer**
Brewster, A. M., Etzel, C., Zhou, R., Wong, Y., Edge, S. B., Blayney, D. W., Wilson, J., Hudis, C., Weeks, J. C., Theriault, R. L.
AMER SOC CLINICAL ONCOLOGY.2009
- **Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer** *Breast Cancer Symposium of the American-Society-of-Clinical-Oncology*
Hassett, M. J., Hughes, M. E., Niland, J. C., Edge, S. B., Theriault, R. L., Wong, Y., Wilson, J., Carter, W. B., Blayney, D. W., Weeks, J. C.
AMER SOC CLINICAL ONCOLOGY.2008: 5553–60
- **Development of the Anemia Impact Measure (AIM): A Disease-Specific Patient Reported outcome (PRO) Instrument to Measure Anemia Symptoms and Their Impact on Functioning in Cancer Patients Receiving Chemotherapy**
Kleinman, L., Benjamin, K., Viswanathan, H., Mattera, M., Bosserman, L. D., Blayney, D. W., Revicki, D.
AMER SOC HEMATOLOGY.2008: 250
- **Continued use of trastuzumab (TRZ) beyond disease progression in the National Comprehensive Cancer Network (NCCN)**
Wong, Y., Ottesen, R., Niland, J., Hughes, M., Theriault, R., Edge, S., Blayney, D., Weeks, J. C.
AMER SOC CLINICAL ONCOLOGY.2008
- **Eighty-five cases of lymphoma in a solid organ transplant (SOT) population: Risk, treatment, and histologic subtype**
Knight, J. S., Tsodikov, A., Cibrik, D. M., Ross, C. W., Kaminski, M. S., Blayney, D. W.
AMER SOC HEMATOLOGY.2007: 411A
- **The registry case finding engine: An automated tool to identify cancer cases from unstructured, free-text pathology reports and clinical notes.** *JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS*
Hanauer, D. A., Miela, G., Chinnaiyan, A. M., Chang, A. E., Blayney, D. W.
2007; 205 (5): 690-697
- **Chemotherapy use for hormone receptor-positive, node-negative breast cancer**
Hassett, M. J., Hughes, M. E., Niland, J. C., Edge, S. B., Theriault, R. L., Wong, Y., Wilson, J., Carter, B. W., Blayney, D. W., Weeks, J. C.
AMER SOC CLINICAL ONCOLOGY.2007
- **Measuring quality with the Quality Oncology Practice Initiative (QOPI) at a university comprehensive cancer center**
Blayney, D. W., Miela, G., Markstrom, D., Hanauer, D., McNiff, K., Neuss, M.
AMER SOC CLINICAL ONCOLOGY.2007
- **Who Will Do the Work? What Work Will They Do?** *JOURNAL OF ONCOLOGY PRACTICE*
Blayney, D. W.
2007; 3 (2): 53
- **Apoptosis and Bcl-2 expression in circulating tumor cells (CTC) from women being treated for metastatic breast cancer**
Smerage, J. B., Doyle, G. V., Budd, T., Schott, A. F., Blayney, D. W., Wicha, M. S., Repollet, M., Terstappen, L., Hayes, D. F.

WICHTIG EDITORE.2007: 81

- **Defining Quality: QOPI Is a Start.** *Journal of oncology practice / American Society of Clinical Oncology*
Blayney, D. W.
2006; 2 (5): 203-?
- **The Registry Case Finding Engine (CaFE): An automated approach for cancer patient identification from unstructured, free-text pathology reports.**
Hanauer, D. A., Chinnaiyan, A. M., Miela, G., Blayney, D. W.
AMER SOC CLINICAL ONCOLOGY.2006: 320S
- **Making the Choice Between Academic Oncology and Community Practice: The Big Picture and Details About Each Career** *JOURNAL OF ONCOLOGY PRACTICE*
Desch, C. E., Blayney, D. W.
2006; 2 (3): 132-136
- **The detection of apoptosis and Bcl-2 expression in circulating tumor cells (CTCs) from women being treated for metastatic breast cancer**
Smerage, J. B., Doyle, G. V., Budd, G., Schott, A. F., Blayney, D. W., Wicha, M. S., Repollet, M., Terstappen, L. M., Hayes, D. F.
AMER ASSOC CANCER RESEARCH.2006
- **Implementation of the quality oncology practice initiative in a hospital-based, University Comprehensive Cancer Center.**
Blayney, D. W., Miela, G., Markstrom, D., Marlin, C. J., Hanauer, D., McNiff, K., Neuss, M., Desch, C., Hayes, D. F.
SPRINGER.2006: S236
- **From the editor's desk** *MATRIX BIOLOGY*
[Anonymous]
2006; 25 (1): 1-2
- **Apoptosis and Bcl-2 expression in circulating tumor cells from women being treated for metastatic breast cancer.**
Smerage, J. B., Doyle, G., Budd, G. T., Wicha, M. S., Schott, A. F., Blayney, D. W., Repollet, M., Terstappen, L. M., Hayes, D. F.
SPRINGER.2006: S214
- **From the Editor's Desk** *JOURNAL OF ONCOLOGY PRACTICE*
Blayney, D. W.
2005; 1 (2)
- **Efficacy of darbepoetin alfa in chemotherapy-induced anemia in gastrointestinal cancers.**
Blayney, D., Vadhan-Raj, S., Tomita, D., Rossi, G., Mirtsching, B.
AMER SOC CLINICAL ONCOLOGY.2005: 781S
- **Efficacy of darbepoetin alfa in the treatment of chemotherapy-induced anemia in Non-Hodgkin's Lymphoma**
Gregory, S. A., Blayney, D. W., Vadhan-Raj, S., Tomita, D. K., Rossi, G., Mirtsching, B.
AMER SOC HEMATOLOGY.2004: 900A-901A
- **Baseline (BL) covariates of response to darbepoetin alfa (DA) every 2 weeks (Q2W) in patients (pts) with chemotherapy-induced anemia (CIA).**
Vadhan-Raj, S., Mirtsching, B., Gregory, S. A., Hong, J., Fessen, M., Yao, B., Rossi, G., Blayney, D.
AMER SOC CLINICAL ONCOLOGY.2004: 744S
- **The relationships between FACT-Fatigue (FACT-F) scores and physical function (PF) in patients (pts) with chemotherapy-induced anemia treated with darbepoetin alfa (DA).**
Cella, D., Evans, W., Wallace, J., Kallich, J., Blayney, D., Vadhan-Raj, S.
AMER SOC CLINICAL ONCOLOGY.2004: 744S
- **Every-2-week darbepoetin alfa improves hemoglobin in anemic patients with cancer undergoing chemotherapy: A stratified analysis by tumor type.**
Blayney, D., Fesen, M., Mirtsching, B. C., Katz, D., Tomita, D., Colowick, A.
AMER SOC HEMATOLOGY.2003: 19B-20B
- **An investigation into the impact of weight on the efficacy of darbepoetin alfa administered as a fixed dose of 200 mcg every 2 weeks (Q2W).**
Heatherington, A., Gabrilove, J., Blayney, D., Tomita, D., Rossi, G.
AMER SOC HEMATOLOGY.2003: 11B

- **Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: A phase II study of the Southwest Oncology Group (SWOG 9349)** *JOURNAL OF CLINICAL ONCOLOGY*
Blayney, D. W., LeBlanc, M. L., Grogan, T., GAYNOR, E. R., Chapman, R. A., Spiridonidis, C. H., Taylor, S. A., Bearman, S. I., MILLER, T. P., Fisher, R. I.
2003; 21 (13): 2466-2473
- **Darbepoetin alfa 3.0 mcg/kg every 2 weeks improves hemoglobin and quality of life in a subset of breast cancer patients in a community-based trial of patients with chemotherapy-induced anemia.**
Blayney, D. W., Vadhan-Raj, S., Mirtsching, B. C., Tomita, D., Colowick, A.
KLUWER ACADEMIC PUBL.2003: S154
- **Optimal use of antiemetics in the outpatient setting - The Grunberg article reviewed** *ONCOLOGY-NEW YORK*
Blayney, D. W.
2002; 16 (10): 1407-1408
- **Dose-intense CHOPx2 therapy of intermediate grade lymphoma - A phase II study of the southwest oncology group (SWOG).**
Blayney, D. W., LeBlanc, M. L., Fisher, R. I.
AMER SOC HEMATOLOGY.2001: 343A
- **Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving chemotherapy (CT), by monthly pamidronate sodium (PAM) (Aredia(R)) infusion**
Theriault, R. L., Horothbagyi, G. N., Porter, L., Blayney, D., Lipton, A., Gluck, S., Wheeler, H., Allan, S., Simeone, J., Seaman, J., Knight, R., Heffernan, M., Reitsma, et al
STOCKTON PRESS.1996: 6
- **DOSE INTENSE MOPP/ABV WITH PROPHYLACTIC FILGRASTIM (G-CSF) TREATMENT OF ADVANCED HODGKINS-DISEASE (HD) - A PILOT-STUDY**
BLAYNEY, D. W., BOSSERMAN, L. D., VAKIL, M.
W B SAUNDERS CO.1994: A638
- **LEUKEMIA AFTER TREATMENT OF OVARIAN-CANCER OR HODGKINS-DISEASE** *NEW ENGLAND JOURNAL OF MEDICINE*
BLAYNEY, D. W., LONGO, D. L.
1990; 322 (25): 1818
- **TUMOR TRAPPING OF 5-FLUOROURACIL - INVIVO F-19 NMR SPECTROSCOPIC PHARMACOKINETICS IN TUMOR-BEARING HUMANS AND RABBITS** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
WOLF, W., PRESANT, C. A., SERVIS, K. L., ELTAHTAWY, A., ALBRIGHT, M. J., BARKER, P. B., RING, R., ATKINSON, D., ONG, R., KING, M., SINGH, M., RAY, M., WISEMAN, et al
1990; 87 (1): 492-496
- **EARLY DETECTION OF CISPLATIN RESISTANCE IN FRESH HUMAN CARCINOMA-CELLS BY INVITRO ENZYMATIC AMPLIFICATION ASSAY**
KASHANISABET, M., ROSSI, J. J., LU, Y., CHEN, J., MIYACHI, H., MA, J. X., BLAYNEY, D., LEONG, L., SCANLON, K. J.
AMER ASSOC CANCER RESEARCH.1988: 292
- **DECREASING RISK OF LEUKEMIA WITH PROLONGED FOLLOW-UP AFTER CHEMOTHERAPY AND RADIOTHERAPY FOR HODGKINS-DISEASE - REPLY** *NEW ENGLAND JOURNAL OF MEDICINE*
BLAYNEY, D. W., DEVITA, V. T., YOUNG, R. C., GREENE, M. H., HUBBARD, S. M., POSTAL, M. G., DUFFEY, P. L., LONGO, D. L.
1987; 317 (11): 708-709
- **DECREASING RISK OF LEUKEMIA WITH PROLONGED FOLLOW-UP AFTER CHEMOTHERAPY AND RADIOTHERAPY FOR HODGKINS-DISEASE** *NEW ENGLAND JOURNAL OF MEDICINE*
Blayney, D. W., Longo, D. L., Young, R. C., Greene, M. H., Hubbard, S. M., Postal, M. G., Duffey, P. L., DeVita, V. T.
1987; 316 (12): 710-714
- **ANTIGENICALLY DEFINED SUBGROUPS OF LYMPHOBLASTIC LYMPHOMA - THEIR RELATIONSHIP TO CLINICAL PRESENTATION AND BIOLOGIC BEHAVIOR**
SHEIBANI, K., NATHWANI, B. N., WINBERG, C. D., BURKE, J. S., SWARTZ, W. G., BLAYNEY, D., VANDELDELDE, S., HILL, L. R., RAPPAPORT, H.
NATURE PUBLISHING GROUP.1987: A72
- **RECOMBINANT INTERLEUKIN-2 (IL2) THERAPY PRODUCES AZOTEMIA, SODIUM RETENTION, HYPOALBUMINEMIA AND EDEMA**
TEXTOR, S. C., MARGOLIN, K., BLAYNEY, D., DOROSHOW, J.

BLACKWELL SCIENCE INC.1987: 220

- **DISTRIBUTION OF LYMPHOCYTES WITH INTERLEUKIN 2 RECEPTORS (TACANTIGENS) IN REACTIVE LYMPHOPROLIFERATIVE PROCESSES, HODGKINS-DISEASE, AND NON-HODGKINS-LYMPHOMAS - AN IMMUNOHISTOLOGIC STUDY OF 300 CASES**
SHEIBANI, K., WINBERG, C., VANDEVELDE, S., BLAYNEY, D., RAPPAPORT, H.
NATURE PUBLISHING GROUP.1987: A72
- **PHASE-II TRIAL OF 4'DEOXYDOXORUBICIN (DXDX) IN ADVANCED GASTRIC (GCA) AND PANCREATIC (PCA) CANCER**
BLAYNEY, D. W., LEONG, L. A., GOLDBERG, D. A., MARGOLIN, K. A., CARR, B. I., AKMAN, S. A., DOROSHOW, J. H.
AMER ASSOC CANCER RESEARCH.1986: 179
- **PHARMACOKINETICS OF HIGH-DOSE FOLINIC ACID (DL-CF) ADMINISTERED BY CONTINUOUS INTRAVENOUS (IV) INFUSION**
NEWMAN, E., DOROSHOW, J., BERTRAND, M., BURGESSON, P., VILLACORTE, D., BLAYNEY, D., GOLDBERG, D., CARR, B., LEONG, L., MARGOLIN, K., CECCHI, G., STAPLES, R.
AMER ASSOC CANCER RESEARCH.1985: 158
- **SCREENING FOR HUMAN T-CELL LEUKEMIA-LYMPHOMA VIRUS - REPLY** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
BLAYNEY, D. W.
1984; 251 (12): 1555
- **THE HUMAN T-CELL LEUKEMIA-LYMPHOMA VIRUS IN THE SOUTHEASTERN UNITED-STATES** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Blayney, D. W., Blattner, W. A., ROBERTGUROFF, M., Jaffe, E. S., Fisher, R. I., Bunn, P. A., PATTON, M. G., RARICK, H. R., Gallo, R. C.
1983; 250 (8): 1048-1052
- **THE HUMAN T-CELL LEUKEMIA LYMPHOMA VIRUS - TIS ASSOCIATION WITH DISEASE IN THE UNITED-STATES**
JAFFE, E. S., BLAYNEY, D. W., BLATTNER, W., COSSMAN, J., ROBERTGUROFF, M., GALLO, R. C.
WILLIAMS & WILKINS.1983: A40
- **ADULT T-CELL LYMPHOMA IN THE UNITED-STATES - A HIGH-GRADE NON-HODGKINS LYMPHOMA ASSOCIATED WITH HUMAN T-CELL LYMPHOMA VIRUS**
BUNN, P., SCHECHTER, G., JAFFE, E., YOUNG, R., BLAYNEY, D., BLATTNER, W., ROBERTGUROFF, M., GALLO, R.
SLACK INC.1983: A404
- **EVIDENCE FOR HUMAN T-LEUKEMIA VIRUS DEFECTON IN PATIENTS WITH THE ACQUIRED IMMUNE-DEFICIENCY SYNDROME**
GELMANN, E. P., BLAYNEY, D., ROBERTGUROFF, M., WONGSTAAL, F., GALLO, R. C.
SLACK INC.1983: A508
- **THE HUMAN T-CELL LEUKEMIA LYMPHOMA VIRUS, LYMPHOMA, LYTIC BONE-LESIONS, AND HYPERCALCEMIA** *ANNALS OF INTERNAL MEDICINE*
Blayney, D. W., Jaffe, E. S., Fisher, R. I., Schechter, G. P., Cossman, J., ROBERTGUROFF, M., Kalyanaraman, V. S., Blattner, W. A., Gallo, R. C.
1983; 98 (2): 144-151
- **THE HUMAN T-CELL LEUKEMIA LYMPHOMA VIRUS ASSOCIATED WITH AMERICAN ADULT T-CELL LEUKEMIA LYMPHOMA** *BLOOD*
Blayney, D. W., Jaffe, E. S., Blattner, W. A., Cossman, J., ROBERTGUROFF, M., Longo, D. L., Bunn, P. A., Gallo, R. C.
1983; 62 (2): 401-405
- **A NEW SUBTYPE OF HUMAN T-CELL LEUKEMIA-VIRUS (HTLV-II) ASSOCIATED WITH A T-CELL VARIANT OF HAIRY-CELL LEUKEMIA** *SCIENCE*
Kalyanaraman, V. S., SARNGADHARAN, M. G., ROBERTGUROFF, M., Miyoshi, I., Blayney, D., Golde, D., Gallo, R. C.
1982; 218 (4572): 571-573
- **CASE 44-1981 - RADIATION-INDUCED PERICARDITIS** *NEW ENGLAND JOURNAL OF MEDICINE*
BLAYNEY, D. W., LONGO, D.
1982; 306 (9): 550